Ollin Biosciences, Inc., a clinical-stage biopharmaceutical company founded in 2023, has closed an oversubscribed $330 million Series B financing round ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE